




What is claimed is:






1. A method of administering a compound of the formula












wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent.

2. A method according to Claim 1 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin; cyclophosphamide; 5-fluorouracil, doxorubicin and taxol.
3. A method according to Claim 1 wherein the compound is selected from the group consisting of:










4. A method according to Claim 3 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.



5. A method of treating or preventing a neoplasia disease comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:













wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent.

6. A method according to Claim 5 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.





7. A method according to Claim 5 wherein the compound is selected from the group consisting of







20016145-032602



8. A method according to Claim 7 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1, a chemotherapeutic agent and a pharmaceutically acceptable carrier.



10. A method according to Claim 5 wherein the neoplasia disease is tumor metastasis.

5 11. A method according to Claim 5 wherein the neoplasia disease treated is solid tumor growth.

12. A method according to Claim 5 wherein the condition treated is angiogenesis.

10 13. A method according to Claim 5 wherein the neoplasia disease is humoral hypercalcemia of malignancy.

10016145-08600